(194 days)
Not Found
No
The document describes a catheter and its accessories for hemodynamic monitoring. The technology mentioned is fiberoptic reflectance spectrophotometry for oxygen saturation monitoring, which is a standard optical method, not AI/ML. There is no mention of any computational analysis or algorithms that would suggest the use of AI or ML.
No.
The device is used for hemodynamic monitoring (blood sampling, pressure monitoring, oxygen saturation measurements), infusion of solutions, and pressure injection of contrast media. These are diagnostic and supportive functions, not direct therapeutic treatments. While infusions can be therapeutic, the device itself is described as a means for infusion, not as a therapeutic agent or treatment modality.
Yes
The device is indicated for "hemodynamic monitoring through blood sampling, pressure monitoring, and oxygen saturation measurements," which are diagnostic activities used to assess a patient's physiological state.
No
The device description clearly details physical components like catheters, lumens, fiberoptics, suture loops, box clamps, and dilators, indicating it is a hardware device with accessories.
Based on the provided text, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to obtain information for diagnostic or monitoring purposes.
- Device Function: The described catheters are invasive devices inserted into a patient's blood vessels. Their primary functions are:
- Hemodynamic monitoring: Measuring pressure and oxygen saturation directly within the bloodstream.
- Blood sampling: Taking blood samples from within the bloodstream.
- Infusion of solutions: Delivering fluids into the bloodstream.
- Pressure injection of contrast media: Injecting contrast agents into the bloodstream.
- Lack of Specimen Examination: While blood samples are taken, the device itself is not described as performing any analysis or examination of the blood sample outside of the body. The oxygen saturation measurement is done in vivo using fiberoptic technology within the catheter.
The device is a central venous catheter with added capabilities for direct, in-vivo monitoring and access to the bloodstream. This falls under the category of an invasive medical device, not an IVD.
N/A
Intended Use / Indications for Use
The EOCVC Catheters are indicated for hemodynamic monitoring through blood sampling, pressure monitoring, and oxygen saturation measurements.
PediaSat Catheters are indicated for hemodynanic nonitoring through blood sampling, pressure monitoring, and oxygen saturation measurements in adults and/or pediatric patients.
The pressure injectable EOCVC Oligon catheters are indicated for short term (
§ 870.1230 Fiberoptic oximeter catheter.
(a)
Identification. A fiberoptic oximeter catheter is a device used to estimate the oxygen saturation of the blood. It consists of two fiberoptic bundles that conduct light at a desired wavelength through blood and detect the reflected and scattered light at the distal end of the catheter.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
February 20, 2018
Edwards Lifesciences LLC Bedalin Lugo Rodriguez Sr. Regulatory Affairs Specialist One Edwards Wav Irvine, California 92614
Re: K172423
Trade/Device Name: Edwards Oximetry Central Venous Catheter (EOCVC), Edwards Oligon Oximetry Central Venous Catheter, PediaSat Oximetry Catheter Regulation Number: 21 CFR 870.1230 Regulation Name: Fiberoptic Oximeter Catheter Regulatory Class: Class II Product Code: DOE, DRE Dated: January 10, 2018 Received: January 17, 2018
Dear Bedalin Lugo Rodriguez:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
1
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
M.A. Wilhelm
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
| DEPARTMENT OF HEALTH AND HUMAN SERVICES | Form Approved: OMB No. 0910-0120 |
|---|---|
| Food and Drug Administration | Expiration Date: 06/30/2020 |
| Indications for Use | See PRA Statement below. |
| Number (if known) |
510(k) I K172423
Device Name
Bdwards Oximetry Central Venous Catheter (EOCVC), Edwards Oligon Oximetry Central Venous Catheter and PediaSat Oxinetry catheters
Indications for Use (Describe)
The EOCVC Catheters are indicated for hemodynamic monitoring through blood sampling, pressure monitoring, and oxygen saturation measurements.
PediaSat Catheters are indicated for hemodynanic nonitoring through blood sampling, pressure monitoring, and oxygen saturation measurements in adults and/or pediatric patients.
The pressure injectable EOCVC Oligon catheters are indicated for short term ( Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@lda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (7/17)
Page 1 of 1
189C Polskining Sarvices (JAL) 443-4740
3
SECTION 5.0 - 510(K) SUMMARY
| Table 5.1: EOCVC and PediaSat Oximetry Catheters | |
|---|---|
| 510(K) Submitter: | Edwards Lifesciences LLC |
| One Edwards Way | |
| Irvine, CA 92614-5686 | |
| Contact Person: | Bedalin Lugo Rodriguez |
| Sr. Regulatory Affairs Specialist Critical Care | |
| One Edwards Way | |
| Irvine, CA 92614 | |
| Bedalin_lugo@edwards.com | |
| Phone: 787-229-5433, fax 949-809-2967 | |
| Date Prepared: | February 19, 2018 |
| Trade name: | Edwards Oximetry Central Venous Catheter (EOCVC), |
| Edwards Oligon Oximetry Central Venous Catheter, | |
| PediaSat Oximetry Catheters | |
| Classification Name: | Fiber Optic Oximeter Catheter (21 CFR 870.1230) |
| Dilator, Vessel, For Percutaneous Catheterization (21 CFR 870.1310) | |
| Regulation Class/ | |
| Product Code: | Class II/ |
| DQE, DRE | |
| Predicate Device(s): | K053609: PreSep (now EOCVC) & PediaSat Oximetry Catheters |
| (Primary Predicate) | |
| K160645: PreSep (now EOCVC) Oligon Oximetry Catheter | |
| (Secondary Predicate) | |
| Device Description: | The Edwards Oximetry Central Venous Catheter is a non-balloon catheter that provides the means for infusion of solutions, measuring pressure, and taking blood samples through the distal lumen (terminates at the catheter tip), the proximal lumen (terminates 7 cm proximal to the tip), and the medial lumen (terminates 5 cm proximal to the tip). Edwards Oximetry Central Venous Catheter also provides the means for continuously monitoring oxygen saturation using an Edwards Lifesciences oximetry monitor or compatible bedside module. |
The PediaSat oximetry catheters are non-balloon catheters that provide the means for infusion of solutions, measuring pressure, and taking blood samples. These catheters also provide the means for continuously monitoring oxygen saturation using an Edwards Lifesciences oximetry monitor or compatible bedside module.
The EOCVC Oligon catheter is a non-balloon catheter that provides the means for infusion of solutions measuring pressure |
| Table 5.1: EOCVC and PediaSat Oximetry Catheters | |
| injecting contrast media, and taking blood samples through the distal lumen (terminates 7 cm proximate to the tip), and the medial lumen (terminates 5 cm proximal to the tip). The EOCVC Oligon catheter also provides the means for continuously monitoring oxygen saturation using an Edwards Lifesciences monitor and compatible bedside module. All catheters are manufactured with a polyurethane-based Oligon polymer (containing silver, platinum, and carbon black) which has antimicrobial properties. | |
| Oxygen saturation is monitored by fiberoptic reflectance spectrophotometry. The amount of light absorbed, refracted, and reflected depends on the relative amounts of oxygenated and deoxygenated hemoglobin in the blood. | |
| The PediaSat Oximetry Catheter is a 3 lumen catheter available with a diameter of 4.5 French (F) and 8 cm in length. The EOCVC Oximetry Catheters are 3 lumen catheters available with a diameter of 8.5F and in lengths of 16 and 20 cm. EOCVC and PediaSat catheters are manufactured from polyurethane. | |
| A suture loop and a specially molded box clamp are provided with each EOCVC (Oligon and non-Oligon) and PediaSat Oximetry Catheter to facilitate suturing of the catheter at the site of insertion. The suture loop and box clamp can be placed anywhere along the catheter body at the discretion of the clinician. | |
| The dilator, included with each catheter, is indicated for enlarging the opening in a vessel for preparation of percutaneous entry of the catheter. | |
| The EOCVC (Oligon and non-Oligon) and PediaSat Kits consist of accessories previously cleared for marketing as well as accessories that are the subject of this submission. | |
| This submission is for clearance of proposed modifications to the accessories (suture loop, box clamp and dilator) for use with the previously cleared EOCVC Oligon (K160645), PreSep (now EOCVC), and PediaSat (K053609) Oximetry Catheter Kits. Additional accessories are listed on table below. | |
| Indications for use/Intended Use: | The EOCVC Catheters are indicated for hemodynamic monitoring through blood sampling, pressure monitoring, and oxygen saturation measurements. |
| | PediaSat Catheters are indicated for hemodynamic monitoring through blood sampling, pressure monitoring, and oxygen saturation measurements in adults and/or pediatric patients. |
| | The pressure injectable EOCVC Oligon catheters are indicated for |
| Table 5.1: EOCVC and PediaSat Oximetry Catheters | |
| | sampling, infusion of solutions, continuous monitoring of oxygen
saturation measurements, pressure injection of contrast media,
and central venous pressure monitoring. |
| | The suture loop and box clamp are intended to be used to facilitate
the suturing the catheter at the site of insertion. |
| | The dilator, included with each catheter, is indicated for enlarging
the opening in a vessel for preparation of percutaneous entry of
the catheter. |
| Comparative
Analysis: | Testing was conducted to compare the performance and
functionality of the EOCVC (Oligon and non-Oligon) and PediaSat
Oximetry Catheter accessories to the predicate device
accessories. The accessories to the EOCVC (Oligon and non-
Oligon) and PediaSat Oximetry Catheters were shown to be safe,
effective, and substantially equivalent to the predicate device for its
intended use. |
| Functional/Safety
Testing: | The accessories to the EOCVC (Oligon and non-Oligon) and
PediaSat Oximetry Catheters have successfully passed functional
and performance testing, including biocompatibility and bench
testing that includes visual inspection, tensile strength, retention
force, insertion test, guidewire passage and dimensional
verifications. |
| Conclusion: | Test data established that the proposed modifications to
accessories have been shown to be equivalent to the predicate
devices for their intended use. |
4
5